粒子束放疗治疗WHO 2级和3级脑膜瘤:上海质子重离子医院的早期经验
该研究纳入2015年5月至2022年3月在上海质子重离子医院接受粒子束放疗的36例WHO 2级(28例)和3级(8例)脑膜瘤患者,中位随访23.3个月,全队列1、2、3年局部控制率分别为92.0%、82.0%、82.0%,WHO 2级局部控制优于3级(P < 0.001),未观察到G3及以上严重毒性,作者认为疗效与毒性均可接受,但需更长随访评估长期结局。
要点
- WHO 2级脑膜瘤1、2、3年局部控制率分别为100%、94.1%、94.1%,优于3级的50%、25%、25%(P < 0.001)。
- 多因素分析显示WHO分级(2级 vs 3级)是局部控制的显著预后因素(p = 0.016)。
- 未观察到G3及以上严重毒性,作者认为粒子束放疗的疗效与毒性均可接受。
核心结论
- 作者认为粒子束放疗治疗WHO 2级和3级脑膜瘤的疗效与毒性均可接受,但需更长随访评估疾病控制、生存及潜在晚期效应的长期结局。
研究设计与样本
- 研究连续非选择纳入2015年5月至2022年3月在上海质子重离子医院接受粒子束放疗的36例WHO 2级(n = 28)和3级(n = 8)脑膜瘤患者,中位年龄48岁。
- 25例为新诊断疾病接受粒子束放疗,11例为进展/复发性疾病,其中5例为再程放疗。
- 30例接受质子放疗,6例接受碳离子放疗,中位剂量60 GyE。
主要发现
- 中位随访23.3个月,全队列1、2、3年局部控制率分别为92.0%、82.0%、82.0%。
- WHO 2级脑膜瘤1、2、3年局部控制率分别为100%、94.1%、94.1%,WHO 3级分别为50%、25%、25%(P < 0.001)。
- 截至分析时,3例患者死亡,均为WHO 3级脑膜瘤。
- 多因素分析显示WHO分级(2级 vs 3级)是局部控制的显著预后因素(p = 0.016)。
- 未观察到G3及以上严重毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要更长随访来评估疾病控制、生存以及潜在晚期效应方面的长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy and safety of particle beam radiotherapy (PBRT) in the management of patients with WHO grade 2 and 3 meningiomas. METHODS: Thirty-six consecutive and non-selected patients with WHO grade 2 (n = 28) and grade 3 (n = 8) meningiomas were treated at the Shanghai Proton and Heavy Ion Center, from May 2015 to March 2022. The median age of the cohort at PBRT was 48 years. There were 25 and 11 patients treated with PBRT in the setting of newly diagnosed diseases and progressive/recurrent diseases, respectively. PBRT was utilized as re-irradiation in 5 patients. Proton radiotherapy (PRT) and carbon-ion radiotherapy (CIRT), with a median dose of 60 Gy-Equivalent (GyE), were provided to 30 and 6 patients, respectively. RESULTS: With a median follow-up of 23.3 months, the local control rates were 92.0%, 82.0%, and 82.0% at 1, 2, and 3 years for the entire cohort, respectively. Patients with WHO grade 2 meningiomas (100%, 94.1%, 94,1% at 1,2,3 years) had a much better local control than those with WHO grade 3 meningiomas (50%, 25%, 25% at 1,2,3 years; P < 0.001). Three patients, all with WHO grade 3 meningiomas, had deceased at the time of this analysis. Multivariate analyses revealed that WHO grade (grade 2 vs. 3) (p = 0.016) was a significant prognosticator for local control. No severe toxicities (G3 or above) were observed. CONCLUSIONS: Treatment-induced efficacy and toxicities to PBRT in WHO grade 2 and 3 meningiomas were both highly acceptable. Longer follow-up is needed to evaluate the long-term outcome in terms of disease control, survival, as well as potential late effects.
引用
- Qiu X, Gao J, Hu J, et al. Particle beam radiotherapy in the treatment of WHO grade 2 and 3 meningiomas: an early experience from Shanghai Proton and Heavy Ion Center. J Neurooncol. 2023. PMID: 37976030. doi:10.1007/s11060-023-04401-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。